Umbralisib
- Generic Name
- Umbralisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H24F3N5O3
- CAS Number
- 1532533-67-7
- Unique Ingredient Identifier
- 38073MQB2A
- Background
Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are r...
- Indication
Umbralisib does not have any approved therapeutic indications.
- Associated Conditions
- -
- Associated Therapies
- -
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT05152459
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT04783415
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 1
- Registration Number
- NCT04692155
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Conditions
- Recurrent Grade 2 Follicular LymphomaRecurrent Splenic Marginal Zone LymphomaRecurrent Waldenstrom MacroglobulinemiaRecurrent Follicular LymphomaRecurrent Nodal Marginal Zone LymphomaRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Mantle Cell LymphomaRefractory Nodal Marginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 1 Follicular Lymphoma
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Yazeed Sawalha
- Registration Number
- NCT04635683
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jennifer R. Brown, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT04624633
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 4
- Registration Number
- NCT04508647
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-03-24
- Target Recruit Count
- 12
- Registration Number
- NCT04163718
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 1
- Registration Number
- NCT04149821
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04016805
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03919175
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.